ENGINEERING MEDICINES TO IMPROVE PATIENT CARE Investors News Releases Year None2022202120202019201820172016 September 2, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 25, 2022 Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering August 17, 2022 Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock August 15, 2022 Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock August 15, 2022 Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates August 15, 2022 Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) August 8, 2022 Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022 August 5, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 8, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 23, 2022 Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 23
Year None2022202120202019201820172016 September 2, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 25, 2022 Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering August 17, 2022 Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock August 15, 2022 Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock August 15, 2022 Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates August 15, 2022 Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) August 8, 2022 Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022 August 5, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 8, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 23, 2022 Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 23
September 2, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2022 Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering
August 17, 2022 Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
August 15, 2022 Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
August 15, 2022 Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
August 15, 2022 Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
August 8, 2022 Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022
August 5, 2022 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)